Bifunctional CDK2/5 Compounds for Selective E3-Mediated Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CDK inhibitors exhibit significant off-target toxicity due to their broad-spectrum activity, limiting their therapeutic window and efficacy in treating diseases like cancer, particularly CDK1-dependent toxicity.
Innovation Solution
Development of bifunctional compounds that selectively target CDK2 and CDK5 through a CDK2/5 ligand conjugated with an E3 ligase binder, promoting dual degradation of these kinases while sparing other CDK isoforms, thereby reducing off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If pan-CDK inhibitors are used to target multiple CDK isoforms, then broad-spectrum CDK inhibition is achieved, but significant off-target toxicity occurs due to inhibition of essential CDKs like CDK1
Solution Approach 1:
The patent segments the CDK inhibition function by designing separate binding pockets in the bifunctional compound: one pocket specifically for CDK2 and another for CDK5. This segmentation allows selective inhibition of these two isoforms while sparing other essential CDKs like CDK1, thereby resolving the contradiction between broad-spectrum inhibition and off-target toxicity.
Solution Approach 2:
The patent applies local quality by creating distinct binding regions within the compound structure - a CDK2-binding moiety and a CDK5-binding moiety, each with specific structural features optimized for its target. This local specialization enables selective inhibition of CDK2 and CDK5 without affecting other CDK isoforms, resolving the toxicity issue while maintaining targeted efficacy.
2Object-affected harmful factors
If CDK inhibitors are designed to target CDK2 and CDK5 specifically, then off-target toxicity is reduced, but the complexity of achieving dual specificity increases
Solution Approach 1:
The patent merges two separate inhibitor functions into a single bifunctional compound molecule. By combining a CDK2-binding moiety and a CDK5-binding moiety connected by a linker, the compound achieves dual specificity while being administered as a single entity, which simplifies delivery and pharmacokinetics compared to using two separate drugs.
Solution Approach 2:
The patent creates a composite molecular structure consisting of two distinct binding moieties with different structural characteristics (one for CDK2, one for CDK5) joined by a flexible linker. This composite design enables the single compound to interact with two different CDK isoforms through different binding interfaces, achieving dual specificity without requiring two separate compounds.
3Manufacturing precision
If bifunctional compounds with separate CDK2 and CDK5 binding pockets are designed, then target selectivity is improved, but the difficulty of synthesizing such complex structures increases
Solution Approach 1:
The patent introduces a linker moiety as an intermediary component that connects the CDK2-binding and CDK5-binding moieties. This linker serves as a flexible bridge that allows the two functional domains to maintain their specific binding capabilities while being part of a single molecule, facilitating the synthesis and assembly of the bifunctional compound.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bifunctional compounds achieve high target selectivity, effectively knocking down CDK2 and CDK5, offering a potential treatment for CDK2/5-mediated diseases with reduced off-target toxicity.
Implementation Method 1
bifunctional compounds that selectively target CDK2 and CDK5 through a CDK2/5 ligand conjugated with an E3 ligase binder, promoting dual degradation of these kinases
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions mediated by dysfunctional cyclin-dependent kinase 2 (CDK2) and CDK5 activity.